NanoViricides, Inc. reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies.
NanoViricides, Inc. reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies.